Breaking the REMS Barrier: The Fight for Fair Drug Competition

Executive Summary

Risk Evaluation and Mitigation Strategies (REMS) are critical drug safety programs mandated by the U.S. Food and Drug Administration (FDA) to ensure that the benefits of certain high-risk medications outweigh their serious risks.¹ While designed to protect public health, REMS, particularly those involving “Elements to Assure Safe Use” (ETASU), have been increasingly exploited by brand-name pharmaceutical companies to erect anti-competitive barriers against generic and biosimilar market entry. These tactics, primarily the refusal to provide drug samples for bioequivalence testing and the deliberate stalling of shared REMS negotiations, undermine the foundational principles of the Hatch-Waxman Act, which was established to expedite generic drug approval.⁶

The economic consequences of this REMS abuse are substantial, with estimates indicating billions of dollars in lost savings annually for the U.S. healthcare system, including federal and state governments, private insurers, and patients.⁷ Beyond financial implications, these delays restrict patient access to more affordable and often essential medicines, imposing burdens on healthcare providers and potentially leading to higher out-of-pocket costs.¹³

In response to these growing concerns, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act was enacted in December 2019.¹⁵ This landmark legislation provides generic and biosimilar manufacturers with a private right of action to sue brand-name companies that unlawfully withhold samples or refuse to engage in shared REMS negotiations, aiming to restore fair competition.⁹ While early litigation under the CREATES Act shows promise in deterring some abusive practices, ongoing legal challenges and the inherent complexities of REMS programs necessitate continued vigilance and potential policy refinements to truly break the REMS barrier and foster a competitive pharmaceutical landscape that benefits patients and the healthcare system.

1. Introduction: The Dual Nature of Risk Evaluation and Mitigation Strategies (REMS)

Risk Evaluation and Mitigation Strategies (REMS) are essential drug safety programs required by the U.S. Food and Drug Administration (FDA) to manage serious risks associated with certain prescription drugs and biologics, ensuring their benefits outweigh their risks.¹ These programs represent a critical component of the FDA’s post-market surveillance and risk management framework, extending beyond standard drug labeling to reinforce safe use.³

Definition and Statutory Basis of REMS

REMS are formalized risk management programs mandated by the FDA to ensure that the benefits of a drug outweigh its inherent risks.¹ The legal authority for the FDA to require REMS stems from Section 505-1 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which was enacted through the Food and Drug Administration Amendments Act (FDAAA) of 2007.¹³ This legislative mandate formalized earlier FDA safety initiatives, such as the Risk Minimization Action Plans (RiskMAPs), which laid the groundwork for the development and implementation of REMS.²⁷ REMS can be required either prior to a drug’s approval or at any point post-approval if new safety information emerges that necessitates additional risk mitigation strategies.²

Primary Purpose: Ensuring Drug Benefits Outweigh Risks

The overarching objective of any REMS program is to mitigate specific serious risks associated with a medication, such as addiction, abuse, misuse, overdose, or severe adverse events like birth defects or severe neutropenia.¹ For example, the Opioid Analgesic REMS specifically aims to reduce the risks of addiction, abuse, and misuse that can lead to overdose and death.¹ Similarly, the Clozapine REMS was designed to mitigate the risk of severe neutropenia associated with the use of that antipsychotic.²⁸ By implementing these risk management programs, REMS are crucial for providing safe access to drugs with serious risks that might otherwise not be approved for market entry or would be withdrawn due to their known or potential adverse profiles.²

Types of REMS and Their Components

REMS programs are highly individualized, tailored to the specific risks of each drug. However, they commonly incorporate several key components designed to communicate information and/or require activities from various participants, including healthcare providers, pharmacists, and patients.⁴

Medication Guides (MedGuides): These are FDA-approved patient handouts that provide essential information in patient-friendly language on how to safely use a medication and avoid serious adverse events. MedGuides are typically distributed to patients when the prescription is dispensed.¹
Communication Plans: These involve direct communications from the drug manufacturer to healthcare providers, pharmacists, nurses, and other participants in healthcare delivery. The purpose is to inform them about specific serious risks associated with the medication and the necessary steps to reduce those risks. Such plans may also target medical professional societies or state licensing boards.⁴
Elements to Assure Safe Use (ETASU): These are more restrictive measures required for drugs with inherent toxicity or a higher potential for harm. ETASU aim to mitigate specific, serious risks listed in the drug’s labeling. They can encompass a range of requirements, including specialized training or certification for prescribers, special certifications for pharmacies or other dispensers, limitations on the types of healthcare settings where the drug can be dispensed, documentation of safe use conditions (e.g., specific lab testing results before dispensing), patient monitoring, and enrollment of patients in a registry.² As of January 2025, a significant majority—94.5%—of active REMS programs incorporate ETASU.¹³
Implementation System: This component involves a system through which the ETASU can be effectively monitored, evaluated, and improved over time.⁴
Timetable for Assessments: Drug manufacturers are required to submit periodic assessment reports to the FDA to determine if the REMS is meeting its risk mitigation goals and whether any modifications are needed.²

The Inherent Tension: Safety vs. Market Access

While REMS are fundamentally designed to provide safe access to high-risk drugs that might otherwise be unavailable to patients ², their stringent requirements, particularly those involving ETASU, can inadvertently create significant barriers to market entry for generic and biosimilar competitors.⁷ This tension between the imperative of patient safety and the promotion of market competition forms the core of the “REMS barrier” problem, which is a central focus of this report.

Deeper Analysis: REMS as a Dynamic Regulatory Tool and a Dual-Use Instrument

The evolution of REMS from earlier FDA safety initiatives, such as Risk Minimization Action Plans (RiskMAPs), demonstrates that the FDA’s approach to drug safety is not static but rather a dynamic and adaptive regulatory process.²⁷ The agency consistently reviews REMS assessments and possesses the authority to modify or even eliminate REMS requirements if they are determined to be no longer necessary to ensure that a drug’s benefits outweigh its risks.² This continuous refinement, including recent guidance updates in 2023 aimed at reducing stakeholder burden through standardized language ¹⁷, indicates the FDA’s ongoing effort to balance emerging safety concerns with practical implementation challenges. This adaptability is crucial for addressing new safety information but also means that the regulatory landscape is constantly shifting, requiring vigilance from all stakeholders.

Furthermore, the very purpose of REMS—ensuring patient safety—has become a contested concept in the context of generic drug competition. While brand manufacturers consistently assert that stringent REMS are crucial for protecting public health and preventing adverse events ¹⁹, generic companies and even regulatory bodies like the Federal Trade Commission (FTC) and the FDA itself have explicitly stated that these safety mechanisms are often

abused to delay competition and protect market monopolies.⁷ This contradiction reveals a deliberate strategic misuse of a public safety mechanism for private commercial gain. The “safety” argument, when employed by brand companies to deny samples or stall shared REMS negotiations, serves as a legal shield, leveraging the inherent complexities and regulatory sensitivities of REMS. The fact that FDA officials themselves acknowledge this “abuse” ⁷ indicates a systemic problem where regulatory tools are being weaponized, moving beyond unintended consequences to intentional anti-competitive conduct. This raises fundamental questions about the adequacy of existing enforcement mechanisms prior to the CREATES Act and highlights the ongoing challenge of discerning genuine safety concerns from anti-competitive intent.

2. REMS as a Barrier to Generic and Biosimilar Competition

Despite their intended purpose of safeguarding public health, REMS programs, particularly those with Elements to Assure Safe Use (ETASU), have been widely criticized for being exploited by brand-name pharmaceutical companies to stifle generic and biosimilar competition.⁶ This subversion of regulatory intent has significant implications for drug pricing and patient access.

2.1. Mechanisms of Abuse

Several tactics are employed by brand-name manufacturers to leverage REMS as a competitive barrier:

Refusal to Provide Samples for Bioequivalence Testing: Generic and biosimilar manufacturers are legally required to conduct bioequivalence and bioavailability studies to demonstrate that their proposed product is therapeutically equivalent to the brand-name reference listed drug (RLD). This testing necessitates access to samples of the brand-name drug, which is a prerequisite for filing an Abbreviated New Drug Application (ANDA) or biosimilar application.⁶ Brand companies frequently refuse to sell these samples, either directly or by imposing unreasonable contract terms or restricting suppliers from selling the product for research purposes.⁷ This refusal is often disguised under the pretext of safety concerns related to the REMS’s restricted distribution system.⁷ The practical effect of this tactic is to make it impossible for generic firms to even submit an application for FDA approval, thereby indefinitely preventing patients from accessing more affordable treatment options.⁷
Refusal to Negotiate Shared REMS Programs: When a brand-name drug has a REMS, any generic version of that drug is legally required to have the same or comparable ETASU.² The FDA generally encourages or requires a single, shared REMS system (SSS REMS) between brand and generic manufacturers to reduce the administrative burden on the healthcare system.² However, brand manufacturers have been known to exploit this preference by prolonging negotiations for shared REMS programs indefinitely, effectively delaying generic market entry even after samples are obtained and ANDAs are approved.⁶ Historically, the FDA rarely granted waivers for separate REMS, which created a strategic incentive for brand firms to refuse cooperation, knowing that generic entry was contingent on their agreement.¹⁰
Establishment of Restricted Distribution Networks: REMS programs, particularly those with ETASU, often involve restricted distribution systems, such as requiring dispensing only through specialty pharmacies or certified healthcare settings.⁶ Brand companies have been accused of creating or exploiting these networks not for genuine safety reasons, but solely to control access to samples and delay generic entry.⁷ Experts have explicitly stated that such actions have “nothing to do with safety but profit”.⁴³
“Evergreening” and Other Tactics to Extend Market Exclusivity: Beyond REMS, brand companies employ broader “evergreening” strategies to extend market exclusivity. This involves filing multiple secondary patents on minor drug modifications (e.g., on its coating or method of administration) to prolong the 20-year patent term.⁵² The misuse of REMS, particularly the refusal to provide samples, is viewed by many as another form of evergreening, effectively delaying generic entry even when intellectual property (IP) rights have lapsed.⁷ The FDA Office of New Drugs Director, Dr. John Jenkins, has explicitly stated that companies are “abusing the system” and that REMS has become an “evergreening system for avoiding generic competition”.⁷

2.2. The Hatch-Waxman Act Context

Brief Explanation of ANDA Process and Bioequivalence Testing: The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, fundamentally reshaped the pharmaceutical landscape by creating an expedited pathway for generic drug approval.⁹ This legislation allows generic manufacturers to submit Abbreviated New Drug Applications (ANDAs), which do not require them to repeat the extensive and costly clinical trials conducted for the original brand-name drug.⁹ Instead, generic applicants must demonstrate bioequivalence to the brand-name Reference Listed Drug (RLD), proving that their product contains the same active ingredient, is in the same dosage form and route of administration, and performs similarly in the body.⁶
How REMS Abuse Undermines the Act’s Intent: The Hatch-Waxman Act was carefully crafted to strike a balance between incentivizing pharmaceutical innovation through patent protection and ensuring timely public access to affordable generic medicines once those protections expire.⁷ REMS abuse directly thwarts this delicate balance. By preventing generic firms from obtaining the necessary samples for bioequivalence testing or by indefinitely delaying shared REMS negotiations, brand manufacturers effectively block or delay FDA approval of generic versions.⁷ This practice subverts the original intent of the Hatch-Waxman Act, transforming regulatory safeguards into a “weapon to block competition” and extending the brand’s monopoly beyond its lawful intellectual property rights.³⁷

Deeper Analysis: Regulatory Loophole Exploitation and the Interplay of IP and Regulatory Barriers

The consistent narrative from generic drug associations, the Federal Trade Commission, and even the FDA itself points to a deliberate exploitation of regulatory gaps. While current law explicitly states that a manufacturer cannot use a REMS program to block or delay approval of a generic drug application ⁷, brand companies have found ways to circumvent this principle. This is achieved by leveraging “regulatory loopholes” ³⁹ or the absence of explicit enforcement mechanisms in the original FDAAA that could compel brand companies to provide samples or engage in good-faith shared REMS negotiations.⁷ This situation highlights a significant disconnect between the

spirit of the law, which aims to promote both patient safety and fair competition, and its practical application, where procedural complexities can be strategically manipulated for anti-competitive ends. Such actions are not accidental byproducts of complex regulation but rather a calculated manipulation of the system, underscoring the need for greater clarity and stronger enforcement.

Furthermore, the issue of REMS abuse reveals a sophisticated, multi-layered strategy employed by brand companies to extend market exclusivity. While traditional patent protections provide a legal monopoly for brand drugs for a defined period ⁵², REMS-related barriers can effectively extend this exclusivity

after patent expiration.⁷ This is distinct from, and in addition to, traditional patent litigation. This dynamic indicates that when traditional intellectual property protections begin to wane, REMS programs become a secondary, regulatory-based defense mechanism. This significantly complicates the competitive landscape for generic and biosimilar manufacturers, as they must navigate not only the complexities of patent law but also intricate FDA regulatory hurdles, often leading to a state of “uncertainty on steroids” for market entry.⁴⁷ This multi-faceted barrier requires a comprehensive policy response that addresses both IP and regulatory dimensions.

3. Economic and Patient Access Consequences

The deliberate exploitation of REMS programs by brand-name pharmaceutical companies to delay generic and biosimilar market entry carries significant economic and public health consequences, imposing substantial costs on the U.S. healthcare system and creating barriers for patients seeking affordable medicines.

3.1. Financial Burden

Quantified Lost Savings Due to Delayed Generic Entry: Studies commissioned by the Association for Accessible Medicines (AAM) have provided quantifiable estimates of the financial burden resulting from REMS abuse. A July 2014 study by Matrix Global Advisors estimated that the ongoing misuse of REMS and “REMS-like” programs cost the U.S. health system $5.4 billion annually.⁷ This figure was based on an analysis of 40 drugs from eight generic manufacturers that faced access blocks.⁷ An updated report in September 2018 revealed that these annual lost savings had escalated dramatically, increasing by 250% in just four years, reaching a staggering total of
$13.4 billion.¹⁰ This rapid escalation underscores a worsening problem in the pharmaceutical market. Of the $13.4 billion,
$3.1 billion was specifically attributed to products restricted by formal REMS programs, while the larger portion, $10.3 billion, stemmed from non-REMS restrictions unilaterally created by brand manufacturers.¹⁰ This clearly indicates that brand companies are proactively establishing their own restricted distribution systems outside of formal FDA-mandated REMS to impede competition.⁷
Impact on Federal Government, Private Insurers, and Out-of-Pocket Costs: The $13.4 billion in annual lost savings is not uniformly distributed but impacts various stakeholders across the healthcare system. The federal government, through programs like Medicare and Medicaid, bears a significant portion, estimated at $5.2 billion.¹² Private insurance plans account for
$2.4 billion in lost savings ¹¹, while state and local governments and other smaller payers collectively lose over
$500 million.¹⁰ Critically, patients themselves face an additional
$1.8 billion in out-of-pocket costs due to these delays.¹² This substantial economic burden highlights that REMS abuse is not merely a corporate dispute but a significant public finance and consumer welfare concern.⁷ Furthermore, the potential lost savings from delayed biosimilar entry are also considerable, estimated at approximately $140 million for every $1 billion in biologics sales.¹¹ Beyond these direct costs, drug diversion and misuse, which REMS are intended to mitigate, also impose substantial costs on the healthcare system, estimated at $72.5 billion annually for payers, with Medicare and Medicaid bearing two-thirds of this burden.⁷³ The delay in generic entry exacerbates these costs by maintaining high brand-name drug prices for longer periods.¹¹

3.2. Patient Access Challenges

Increased Drug Prices and Reduced Affordability: The most direct consequence of delayed generic entry is the sustained high cost of brand-name drugs, which prevents the significant cost savings that generics are known to deliver. Generic drugs typically cost 75-85% less than their brand counterparts.¹¹ This directly translates to higher out-of-pocket costs for patients, making essential medicines less affordable and, in some cases, inaccessible.⁷ A notable statistic from 2022 indicates that 15% of adults reported foregoing medical care, prescription drugs, or mental health care due to cost.⁷⁴
Burdens on Healthcare Providers and Pharmacies Due to Complex REMS Requirements: The inherent complexity and elaborate requirements of certain REMS programs impose significant administrative burdens and time commitments on healthcare providers (HCPs) and pharmacies.¹³ Requirements such as specialized training, certification, patient enrollment, and extensive documentation can hinder the smooth and efficient delivery of care and access to medications.¹³ Some physicians have even expressed reluctance to prescribe opioids covered under REMS due to the perceived difficulty of complying with the mandates.⁷³ Furthermore, if a shared REMS system is not agreed upon, the need for separate REMS programs for brand and generic versions can create additional inefficiencies, requiring HCPs and pharmacies to enroll in multiple programs and manage different reporting requirements, thereby complicating patient care.⁵¹
Specific Examples of Patient Access Issues:

Opioid Analgesics: The Opioid Analgesic REMS aims to mitigate the risks of addiction, abuse, and misuse through comprehensive HCP education and patient guidance on safe use, storage, and disposal.¹ While critical for public health, the complexity of managing opioid prescriptions under REMS can still present challenges for patient access, despite ongoing efforts to streamline processes, such as the provision of mail-back envelopes for drug disposal mandated by March 2025.³¹
Clozapine: The Clozapine REMS, initially approved in September 2015, mandated strict monitoring of Absolute Neutrophil Count (ANC) levels due to the risk of severe neutropenia associated with the antipsychotic.²⁸ This requirement involved frequent blood draws for patients, which could be burdensome.³² In March 2025, the FDA removed the REMS requirement for ANC reporting, concluding that the program was no longer necessary to ensure the drug’s benefits outweighed its risks. This decision, based on expert advice, is expected to decrease the burden on the healthcare delivery system and consequently improve patient access to clozapine.³⁰
Endothelin Receptor Antagonists (ERAs): In April 2025, the FDA eliminated REMS requirements related to embryofetal toxicity (EFT) risk for several ERA medicines, including Ambrisentan and Macitentan-containing products.⁴¹ This decision was predicated on two decades of human pregnancy data that did not show a consistent pattern of congenital malformations, indicating that standard labeling alone was sufficient to communicate the risk. This regulatory change directly reduced the burdens on prescribers, pharmacies, and patients, improving access to these medications.⁴¹
Mifepristone: A petition filed by several state Attorneys General in June 2025 urged the FDA to eliminate “unnecessary and outdated restrictions” on mifepristone, an abortion medication.⁶² They argue that the current REMS, which includes patient agreement forms and complex pharmacy certification, is “medically unnecessary and unduly burdensome on patient access,” particularly in rural and medically underserved areas, and dissuades pharmacies from carrying the drug.⁶² While the FDA had previously modified the mifepristone REMS to eliminate in-person dispensing requirements in 2021 (formalized in 2023), further restrictions are still seen as impeding access despite the drug’s established safety record.¹³
Cell Therapy (e.g., Breyanzi, Abecma): In June 2025, the FDA approved the removal of REMS programs and streamlined patient monitoring requirements for certain cell therapy treatments.⁴² This change was driven by the medical hematology/oncology community’s extensive experience in managing associated risks. The aim is to reduce the burden on healthcare delivery systems and improve patient access, particularly for those living far from certified treatment centers, thereby increasing the uptake of these “life-saving therapies”.⁴²

Deeper Analysis: The Hidden Cost of “Safety” and REMS as a Double-Edged Sword for Patient Access

The extensive data on lost savings due to REMS abuse reveals a critical dynamic: while REMS are ostensibly designed for safety, their strategic misuse by brand manufacturers directly translates into a quantifiable, multi-billion dollar economic burden on the entire U.S. healthcare system.⁷ This financial impact provides a compelling economic argument for legislative and regulatory intervention, shifting the debate from a purely safety-focused discussion to one that encompasses economic efficiency and broader public welfare. The cost is not merely an unintended side effect, but a direct consequence of anti-competitive behavior enabled by the REMS framework.

Furthermore, the detailed examples of REMS programs illustrate that while these strategies are intended to enable access to high-risk drugs that might otherwise be unavailable ², their implementation or over-stringency can paradoxically

restrict access or create undue burdens for patients and healthcare providers.¹³ This presents a significant policy challenge: ensuring that safety measures are proportionate to the actual risk and do not inadvertently create new barriers to care. The FDA’s recent actions to remove or streamline certain REMS (e.g., clozapine, ERAs, cell therapies) demonstrate a recognition of this problem and an active attempt to re-balance the scales, suggesting a positive trend towards more adaptive and less burdensome REMS where justified by real-world safety data. This continuous reassessment is vital to ensure REMS fulfill their safety mandate without unduly compromising patient access to essential medications.

Table 1: Estimated Annual Lost Savings from REMS and Restricted Access Abuse (2014 vs. 2018)

Category of Lost Savings	2014 Estimate (Annual)	2018 Estimate (Annual)	Percentage Increase (2014-2018)	Relevant Snippets
Total U.S. Health System	$5.4 billion	$13.4 billion	250%	⁷
Federal Government	$1.8 billion	$5.2 billion	~189%	⁷
Patient Out-of-Pocket	Not specified in 2014	>$1.8 billion	N/A	¹²
Private Insurance	$2.4 billion	Not specified in 2018	N/A	¹¹
State/Local & Other Payers	$0.24 billion	>$0.5 billion	~108%	¹⁰

Value of Table 1: This table is highly valuable as it quantifies the direct financial impact of REMS abuse, which is a central aspect of the user’s query. By presenting specific, quantifiable figures on lost savings from both 2014 and 2018, it vividly illustrates the scale and growth of the problem. The dramatic 250% increase in total lost savings from $5.4 billion to $13.4 billion in just four years is a critical, high-impact statistic that underscores the escalating nature of anti-competitive tactics. Furthermore, breaking down these lost savings by payer type (federal government, private insurance, patient out-of-pocket, and state/local entities) clearly demonstrates who bears the financial burden, reinforcing that this issue extends beyond a mere corporate dispute to a significant public finance and consumer welfare concern. This concrete evidence strengthens the argument for urgent legislative and regulatory intervention.

Table 2: Examples of REMS Programs and Associated Patient Access Considerations

Drug/Class	Primary Risk Mitigated	Key REMS Components (Examples)	Patient Access Considerations/Issues	Current Status (if applicable)	Relevant Snippets
Opioid Analgesics	Addiction, Abuse, Misuse, Overdose, Death	HCP education, Patient Medication Guides, Safe disposal options (mail-back envelopes)	Aims to ensure safe access while mitigating risks; potential for burden on HCPs/patients due to complexity.	Ongoing; 2023 Blueprint update, mail-back envelope requirement by March 2025.	¹
Clozapine	Severe Neutropenia	ANC monitoring, centralized system for prescribers/pharmacists	Historically burdensome (weekly blood draws); deterring use despite efficacy.	REMS requirement for ANC reporting removed March 2025 to improve access.	²⁸
Endothelin Receptor Antagonists (ERAs)	Embryofetal Toxicity	Patient enrollment, restricted distribution (historical)	Burdensome requirements for patients/HCPs.	REMS related to EFT risk eliminated April 2025; labeling deemed sufficient.	⁴¹
Mifepristone	(Perceived) Safety Concerns	Prescriber/pharmacy certification, patient agreement forms, in-person dispensing (historical)	Medically unnecessary, unduly burdensome, impedes access, especially in rural areas; dissuades pharmacies.	Petition filed June 2025 to eliminate REMS; in-person dispensing requirement lifted in 2021/formalized 2023.	⁶²
Cell Therapy (e.g., Breyanzi, Abecma)	Cytokine Release Syndrome (CRS), Neurologic Toxicities (NTs)	Patient monitoring requirements, proximity to treatment centers (historical)	Onerous requirements discouraged patients, particularly those far from centers.	REMS programs removed June 2025; patient monitoring streamlined.	⁴²

Value of Table 2: This table is highly valuable because it provides concrete, illustrative examples of how REMS programs, despite their safety intent, can create or exacerbate patient access issues. By detailing specific drugs, their associated risks, the REMS components, and the resulting access challenges, the table moves beyond general statements to offer tangible evidence. The “Current Status” column is particularly insightful, as it highlights the dynamic nature of REMS and the FDA’s responsiveness to concerns about undue burden. The removal or streamlining of REMS for drugs like Clozapine, ERAs, and cell therapies demonstrates a recognition by the FDA that some REMS may become unnecessary or overly burdensome over time, providing a nuanced perspective on the ongoing “fight” and potential for positive change.

4. Legislative and Regulatory Responses: The CREATES Act

The escalating economic and patient access consequences of REMS abuse spurred significant legislative and regulatory action, most notably the enactment of the CREATES Act. These responses aim to provide clearer legal pathways and enhance regulatory oversight to counter anti-competitive practices.

4.1. Genesis and Purpose of the CREATES Act

The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, initially introduced in 2016 ⁶, was ultimately enacted in December 2019 as Section 610 of Division N of the Further Consolidated Appropriations Act of 2020.¹⁵ This landmark legislation was specifically designed to counteract abusive delay tactics employed by brand-name drug companies, primarily their refusal to provide necessary drug samples for bioequivalence testing and their prolonged obstruction of shared REMS negotiations.⁷

The core of the CREATES Act is the establishment of a “private right of action”.⁹ This provision empowers generic and biosimilar manufacturers to sue brand companies that unlawfully refuse to sell them product samples needed to support their applications, compelling the sale of samples on “commercially reasonable, market-based terms”.⁹ If the generic developer prevails in such a lawsuit, the court can order the sale of samples, award attorneys’ fees and litigation costs to the product developer, and may impose a monetary penalty on the brand company to deter future refusals.¹⁵ For products subject to REMS with Elements to Assure Safe Use (ETASU), a crucial prerequisite for generic developers before filing a lawsuit is to first obtain a “Covered Product Authorization” (CPA) from the FDA.¹⁵

Beyond sample access, the CREATES Act also addresses the issue of shared REMS programs. It grants the FDA more discretion to approve alternative safety protocols for generic drugs, rather than strictly mandating a single, shared system, particularly in instances where the brand manufacturer refuses to negotiate in good faith or if an aspect of the REMS is claimed by an unexpired patent or trade secret.⁷ This provision aims to prevent brand manufacturers from indefinitely delaying generic market entry by prolonging shared REMS negotiations.

4.2. FDA’s Role and Guidance

The FDA has openly acknowledged the problem of REMS abuse. High-ranking officials, such as Dr. John Jenkins, former Director of the FDA’s Office of New Drugs, and Dr. Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research, have publicly characterized REMS abuse as a “growing major problem” that has “delayed the availability of generics”.⁷

Prior to the enactment of the CREATES Act, the FDA had attempted to address the issue through guidance. For instance, in 2014, the agency issued draft guidance on how generic companies could obtain an FDA opinion letter stating that the agency would not consider it a REMS violation for brand companies to provide reference standard drug samples for testing if the generic’s protocols complied with safety standards.⁹ However, these letters, while indicating FDA’s stance, did not legally compel brand companies to provide samples, and their legal effect in court was often disputed.⁹

In a more proactive effort to streamline REMS processes and reduce opportunities for abuse, the FDA has issued specific guidances related to shared REMS and waivers:

“Development of a Shared System REMS” Guidance (Draft June 2018): This guidance provides recommendations to industry on the development of shared system REMS for multiple prescription drug products. It highlights the benefits of shared systems, such as reduced administrative burden for stakeholders (e.g., a single portal for materials, one-time certification for healthcare providers and pharmacies) and the potential for cost sharing among sponsors.² The FDA actively facilitates kick-off meetings and communications between brand and generic applicants to encourage the formation of shared systems.¹⁸
“Waivers of the Single, Shared System REMS Requirement” Guidance (Draft May 2018): This guidance outlines the specific conditions under which the FDA may grant a waiver of the single, shared system requirement. Such waivers may be granted if the FDA determines that the burden of creating an SSS outweighs its benefits, or if an aspect of the ETASU is protected by an unexpired patent or trade secret and the generic applicant certifies that they sought but could not obtain a license for its use.⁸

Beyond formal guidance, the FDA has also employed transparency initiatives, such as publicly identifying brand-name drug companies that abuse safety programs or create their own restricted distribution systems to delay competition. These “name and shame” lists, first released in May 2018, aim to increase public and regulatory scrutiny on these practices.¹²

Deeper Analysis: Legislative Empowerment of Enforcement and the Evolving Role of FDA

The enactment of the CREATES Act represents a pivotal moment in addressing REMS abuse, primarily because it directly addresses the previous lack of effective enforcement mechanisms. Before CREATES, FDA officials openly expressed frustration over the absence of “strong enough” tools to compel brand companies to cooperate.⁷ The Act’s creation of a “private right of action” directly fills this void by empowering generic companies to seek judicial remedies. This effectively shifts a significant portion of the enforcement burden from a potentially under-resourced FDA to the private sector, allowing generic manufacturers to directly challenge anti-competitive practices in court. This legislative intervention signals a clear intent to establish a more robust deterrent against REMS abuse by providing a clear legal pathway and imposing financial penalties for non-compliance.

Concurrently, the FDA’s role in this evolving landscape has also adapted. While the CREATES Act provides a legal avenue, the FDA’s function remains crucial, particularly in issuing Covered Product Authorizations (CPAs) for ETASU drugs before a lawsuit can proceed.¹⁵ This positions the FDA as a vital gatekeeper, ensuring that patient safety protocols are adequately addressed even as competition is promoted. Furthermore, the FDA’s proactive issuance of guidance on shared systems and waivers indicates a strategic move to minimize the

opportunity for abuse by streamlining processes and offering alternatives to potentially stalled negotiations. This suggests a more integrated approach where legislative tools like CREATES complement and reinforce regulatory oversight, working in tandem to achieve both drug safety and market competition goals. The agency is moving from a reactive position of merely acknowledging abuse to a more proactive stance of facilitating solutions and acting as a critical safety checkpoint within the legal framework.

Table 3: Key Provisions of the CREATES Act and Their Intended Impact

Provision	Description	Intended Impact on REMS Barriers	Relevant Snippets
Private Right of Action for Sample Access	Allows generic/biosimilar developers to sue brand manufacturers who refuse to sell samples for bioequivalence testing on commercially reasonable terms.	Directly addresses the “refusal to deal” tactic, enabling generic firms to obtain necessary samples and proceed with ANDA/BLA development. Imposes financial penalties and legal costs on non-compliant brand companies.	⁹
Covered Product Authorization (CPA)	For REMS with ETASU, generic developer must first obtain FDA authorization that their testing protocols are comparable and safe before suing for samples.	Ensures patient safety is maintained while facilitating sample access; FDA acts as a safety gatekeeper, preventing frivolous claims.	⁷
Flexibility for Separate REMS Programs	Removes the strict requirement for a single, shared REMS system, allowing FDA more discretion to approve separate, comparable REMS programs for generics/biosimilars.	Prevents brand manufacturers from indefinitely delaying generic entry by prolonging shared REMS negotiations. Reduces the leverage of brand companies to block competition through this mechanism.	⁷
Indemnification for Brand Manufacturers	Provides an affirmative defense and specific indemnification for brand manufacturers from liability arising from generic manufacturers’ handling of samples under the Act.	Addresses brand concerns about liability during generic testing, aiming to remove a key justification for sample denial.	⁷

Value of Table 3: This table is highly valuable as it systematically breaks down the key provisions of the CREATES Act, which is central to the user’s inquiry. For each provision, it clearly articulates what the provision entails and how it is specifically intended to address the identified REMS-related barriers to competition. This provides a clear, actionable understanding of the legislation’s mechanics and its direct impact on the pharmaceutical market. The table clarifies the specific legal tools now available to generic companies and the enhanced discretion granted to the FDA, illustrating a significant shift in the legal landscape. It also highlights the legislative intent to balance patient safety with promoting competition by including provisions like the Covered Product Authorization and indemnification for brand manufacturers.

5. Legal Landscape and Enforcement Actions

The legal battle over REMS abuse has evolved significantly, from complex antitrust lawsuits with uncertain outcomes to a more direct statutory enforcement mechanism under the CREATES Act. Federal agencies like the Federal Trade Commission (FTC) have also played a crucial role in advocating for fair competition.

5.1. Pre-CREATES Act Litigation

Before the enactment of the CREATES Act, generic drug companies frequently resorted to federal court, initiating antitrust lawsuits against brand-name companies that refused to provide samples of REMS-restricted drugs.⁶ These cases often highlighted the challenges generic manufacturers faced in obtaining the necessary materials for bioequivalence testing.

Notable Cases:

Lannett Co. v. Celgene Corp.: As early as 2008, Lannett Co. accused Celgene Corp. of violating the Sherman Act by refusing to sell samples of its cancer medication Thalomid (thalidomide), which was subject to a restricted distribution system.⁶ This case was eventually dismissed following a settlement between the parties.⁶
Actelion Pharmaceuticals Ltd. v. Actavis, Apotex, and Roxane Laboratories: In 2011, Actelion Pharmaceuticals preemptively sued generic firms Apotex and Roxane, seeking a declaratory judgment that it was under “no duty or obligation” to supply samples of its brand-name drugs, Tracleer (bosentan) and Zavesca, both covered by REMS.⁶ The Federal Trade Commission (FTC) intervened in this case by filing an amicus brief, arguing that the improper use of restricted drug distribution programs could impede generic competition and that the generic firms’ antitrust claims were not legally barred.⁴⁴ This lawsuit was also ultimately dismissed after a settlement.⁶
Mylan Pharmaceuticals Inc. v. Celgene Corp.: In April 2014, Mylan Pharmaceuticals filed a comprehensive antitrust lawsuit against Celgene, alleging violations of federal and state antitrust laws. Mylan contended that Celgene was preventing generic competition for its drug products, Revlimid (lenalidomide) and Thalomid (thalidomide), by using their respective REMS as a pretext to deny Mylan access to necessary samples for bioequivalence studies.⁴³ Mylan’s complaint detailed Celgene’s alleged scheme to continuously prevent or stall efforts to obtain samples, even after the FDA had determined Mylan’s safety protocols for testing were acceptable.⁴⁸ The lawsuit sought injunctive relief to compel Celgene to sell samples and compensatory damages for lost sales.⁴⁸
Challenges in Obtaining Clear Judicial Language: A significant challenge in these pre-CREATES Act cases was that prior court decisions and legal settlements often “failed to clarify when REMS drug samples must be supplied”.⁶ This judicial ambiguity underscored the pressing need for more definitive legislative action to establish clear rules for sample access.

5.2. Post-CREATES Act Litigation

The enactment of the CREATES Act in December 2019 fundamentally altered the legal landscape by establishing a direct “private right of action” for generic developers to sue brand companies for refusal to provide samples.¹⁵ This mechanism was specifically designed to offer a more efficient and direct remedy compared to the complex and often protracted antitrust lawsuits that characterized the pre-CREATES Act era.⁶

Analysis of Early Cases (e.g., Teva v. Amicus Therapeutics):

The first lawsuit to test the provisions of the CREATES Act was filed by Teva Pharmaceuticals against Amicus Therapeutics in the Eastern District of Pennsylvania in July 2021.⁷⁷ Teva alleged that Amicus refused to provide “sufficient quantities” of its Fabry disease treatment, Galafold (migalastat), which Teva contended was necessary to support its ANDA application.⁷⁷
The dispute began in August 2020 when Teva initially requested two wallet packs of Galafold. Amicus did not supply these until April 2021, significantly exceeding the 31-day deadline stipulated by the CREATES Act.⁷⁷ Teva then sent a second request for an additional 25 wallet packs for analytical and bioequivalence testing, which Amicus refused, offering only two additional packs instead.⁷⁷
The case was resolved relatively quickly, with Teva dismissing its suit after Amicus agreed to provide the requested quantities of Galafold.⁸⁰
Interpretation of “Sufficient Quantities” and Other Legal Ambiguities: While the swift resolution of Teva v. Amicus suggests the CREATES Act’s potential as a deterrent, it left unresolved a key legal ambiguity: what precisely constitutes “sufficient quantities” of a drug that a brand manufacturer must provide under the law.⁷⁷ The Act defines “sufficient quantities” as “an amount of a covered product that the eligible product developer determines allows it to (A) conduct testing to support an application… and (B) fulfill any regulatory requirements relating to approval of such an application”.⁷⁷ This definition places the determination largely with the generic developer. Future CREATES Act cases are likely to litigate this definition, as well as the scope of “ancillary materials” a generic producer can request and the precise definition of a “covered product” under the Act.⁷⁷ The Act also outlines specific procedural requirements for a valid request (e.g., directed to a named corporate officer, identifying a point of contact, specifying a mailing address) and provides an affirmative defense for brand companies that make a qualifying offer within 14 days of a request.⁷⁷

5.3. Federal Trade Commission (FTC) Involvement

The Federal Trade Commission (FTC) has consistently been a vocal critic of REMS misuse, expressing “very concerned about potential abuses by branded pharmaceutical companies of REMS or other closed distribution systems to impede generic competition”.⁶ The FTC’s involvement underscores the broader economic and antitrust implications of these practices.

Amicus Briefs and Enforcement Priorities: The FTC has actively engaged in pre-CREATES Act cases by filing amicus briefs, such as in the Actelion lawsuit. In these briefs, the FTC argued that a monopolist’s refusal to sell to potential competitors may, under certain circumstances, violate Section 2 of the Sherman Act, and that distribution agreements between brand manufacturers and distributors could violate Section 1 of the Sherman Act.⁴⁴ The FTC views REMS misuse as an “unfair method of competition” ⁸² and has emphasized that it is an “appropriate area for Congressional focus and concern,” warning that such tactics “can potentially delay entry indefinitely”.¹⁰ The FTC’s enforcement priorities extend beyond REMS to other anti-competitive practices in the pharmaceutical sector, including the improper listing of patents in the FDA’s “Orange Book” ⁸², further demonstrating its commitment to fostering generic competition and protecting consumers.

Deeper Analysis: The Shift from Indirect to Direct Legal Recourse and the Deterrent Effect

The evolution of the legal landscape from pre-CREATES Act litigation to the current framework marks a significant shift from indirect to direct legal recourse. Before the CREATES Act, generic companies were compelled to rely on complex antitrust claims, often alleging violations of the Sherman Act for refusal to deal or anti-competitive distribution agreements.²⁹ These cases were notoriously difficult to win, often resulting in settlements that failed to establish clear judicial precedent for when REMS drug samples must be supplied.⁶ The CREATES Act directly addresses this by creating a specific statutory cause of action for sample access, bypassing the need for generic companies to prove complex antitrust violations.⁹ This streamlining of legal recourse makes it easier and potentially faster for generic companies to challenge sample denials, shifting the legal battleground from broad antitrust principles (with their high evidentiary burdens) to a more focused statutory claim, which increases the likelihood of successful generic entry.

The quick resolution of the first lawsuit filed under the CREATES Act, Teva v. Amicus Therapeutics ⁸⁰, suggests a strong deterrent effect. Brand companies may now be more inclined to comply with sample requests rather than face the costs of litigation, attorneys’ fees, and potential monetary penalties stipulated by the Act.¹⁵ This indicates that the Act has indeed provided generic manufacturers with the necessary leverage to obtain fair, market-based access to samples.⁷ However, the fact that this initial case did not definitively resolve the meaning of “sufficient quantities” ⁷⁷ highlights that while the Act is powerful, its full impact will depend on future judicial interpretations of its terms. The “fight” is not over; it has merely shifted from

whether samples can be obtained to how much and under what precise terms. This suggests that future litigation will continue to shape the boundaries of fair competition under the CREATES Act, as both sides seek clarity on its scope and application.

Table 4: Notable REMS-Related Litigation Cases and Their Status/Outcome

Case Name (Plaintiff v. Defendant)	Key Drugs Involved	Allegation(s)	Pre/Post-CREATES Act	Status/Outcome	Relevant Snippets
Lannett Co. v. Celgene Corp.	Thalomid (thalidomide)	Refusal to sell samples, Sherman Act violation.	Pre-CREATES Act (2008)	Dismissed after settlement.	⁶
Actelion Pharms Ltd. v. Actavis, Apotex, Roxane	Tracleer (bosentan), Zavesca	Preemptive suit seeking declaration of no duty to supply samples.	Pre-CREATES Act (2011)	Dismissed after settlement; FTC filed amicus brief.	⁶
Mylan Pharmaceuticals Inc. v. Celgene Corp.	Revlimid (lenalidomide), Thalomid (thalidomide)	Refusal to sell samples, antitrust violations; using REMS as pretext.	Pre-CREATES Act (2014)	Judge allowed suit to proceed; ongoing at snippet date.	⁴⁷
Teva Pharmaceuticals v. Amicus Therapeutics Inc.	Galafold (migalastat)	Refusal to provide “sufficient quantities” of samples under CREATES Act.	Post-CREATES Act (2021)	Teva dismissed suit after Amicus agreed to provide samples.	⁷⁷

Value of Table 4: This table is highly valuable as it provides a concise yet comprehensive overview of key litigation cases related to REMS abuse, clearly distinguishing between those that occurred before and after the enactment of the CREATES Act. By outlining the specific drugs involved, the primary allegations, and the status or outcome of each case, the table effectively illustrates the historical challenges generic companies faced in seeking legal redress. More importantly, it highlights the significant shift in legal strategies post-CREATES Act, demonstrating how the new legislation has provided a more direct and potentially swifter legal remedy. This concrete evidence of legal action underscores the intensity of the “fight” for fair drug competition and the evolving mechanisms employed to address anti-competitive practices.

6. Industry Perspectives and Future Outlook

The debate surrounding REMS and generic competition is characterized by distinct perspectives from brand-name and generic pharmaceutical manufacturers, each emphasizing different priorities and concerns. Understanding these viewpoints is crucial for comprehending the ongoing dynamics and anticipating future developments.

Arguments from Brand-Name Manufacturers Regarding Safety and Necessity of Stringent REMS

Brand-name pharmaceutical companies consistently assert that REMS programs are indispensable tools for managing the serious risks associated with their complex or potent medications. They argue that stringent REMS are critical for ensuring patient safety and, in many cases, are the very reason these drugs can remain available on the market.¹ From this perspective, REMS are seen as vital for protecting public health by preventing severe adverse events, such as birth defects or prolonged hospitalization, and mitigating risks like misuse and diversion.²⁰

Brand manufacturers also raise concerns about potential liability for any harm caused during generic bioequivalence testing if they were compelled to provide samples without adequate safeguards, viewing this as a valid business justification for refusing to deal with potential competitors.²⁹ Furthermore, they emphasize that intellectual property (IP) rights, including patents, are fundamental to allowing pharmaceutical manufacturers to recoup the substantial investments made in research and development (R&D) and extensive clinical trials required for drug approval.⁶⁴ From this viewpoint, mandating a “forced sale” of REMS-restricted drugs for testing could compromise patient safety and potentially divert drugs to parties who may not adhere to the necessary safety requirements.²⁰

Generic Industry’s Advocacy for Fair Competition (e.g., AAM’s Reports)

In stark contrast, the generic pharmaceutical industry, primarily represented by the Association for Accessible Medicines (AAM, formerly GPhA), strongly advocates for fair competition. AAM maintains that its members fully support FDA-mandated REMS programs when they are used for their intended public health purpose of ensuring that a drug’s benefits outweigh its risks.⁷

However, AAM actively campaigns against what it describes as the “misuse” or “abuse” of REMS programs by brand companies to block generic and biosimilar competition.⁷ They consistently highlight that tactics such as withholding samples and prolonging shared REMS negotiations are anti-competitive and impose a significant financial burden, costing patients, payers, and government programs billions of dollars annually.⁷ Generic manufacturers assert their unwavering commitment to patient safety and emphasize their extensive experience in developing products with high safety profiles, arguing that they are fully capable of safely handling REMS-covered drugs for testing purposes.⁷

Ongoing Challenges in Shared REMS Development and Implementation

Despite the FDA’s guidance and efforts to encourage shared REMS systems, significant challenges persist in their development and implementation.¹⁸ The negotiation process for shared REMS can be highly complex, particularly when multiple players are involved, and frequently encounters sticking points related to fundamental business arrangements such as cost-sharing, voting rights, confidentiality agreements, product liability concerns, and antitrust considerations.¹⁸

The FDA’s role in these business arrangements is inherently limited; while the agency facilitates meetings and sets timeframes for milestones, it does not arbitrate substantive disputes about contractual terms.¹⁸ This limitation can lead to prolonged impasses. Furthermore, the FDA acknowledges that if waivers for separate REMS are granted, the resulting multiple REMS systems can create an added burden for healthcare providers, who must then navigate different requirements for essentially the same drug.⁵¹ This highlights a tension between the desire for competitive entry and the practical realities of healthcare delivery.

Role of Competitive Intelligence Tools (e.g., DrugPatentWatch) in Navigating the Landscape

In this complex and often contentious environment, competitive intelligence (CI) platforms have become increasingly crucial for generic and biosimilar manufacturers seeking to navigate the regulatory and competitive landscape.⁶⁹ Tools like DrugPatentWatch provide comprehensive, actionable data on drug patents, generic entry opportunities, patent litigation, regulatory status, and broader market dynamics.⁶⁶

Specifically, such platforms can assist generic companies in several critical ways:

Identifying Market Opportunities: By monitoring patent expiration dates and pipeline developments, these tools help anticipate future opportunities for generic entry.⁸⁵
Navigating Litigation: They track patent litigation and Paragraph IV challenges, which are key indicators for predicting generic launch timing and assessing legal risks.⁶⁶
Regulatory Insight: Access to detailed regulatory status information, including data from the FDA and Patent and Trademark Office, helps ensure compliance and informs regulatory strategies.⁸⁸
Strategic Planning: The data can inform strategies for developing independent REMS programs by providing insights into their complexities and costs.⁵⁰
Advocacy Support: By quantifying the economic impact of delayed generic entry, these tools provide valuable data for advocacy efforts and strategic partnerships aimed at promoting fair competition.⁵⁰

While general search engines like Google Patents can offer a starting point, more specialized and secure competitive intelligence tools are recommended for sensitive patent research due to their comprehensive databases, frequent updates, and enhanced security features.⁶⁹

Deeper Analysis: The “Trust Gap” and Competitive Intelligence as an Asymmetry Corrector

The persistent challenges in shared REMS development frequently stem from a fundamental “trust gap” between brand and generic competitors.⁵⁶ Beyond the objective business arrangements concerning cost-sharing and governance, a deep-seated lack of mutual trust can act as a significant, often unstated, barrier to cooperation. This suggests that purely regulatory or legislative solutions, while necessary, may not fully resolve the shared REMS problem. Overcoming these entrenched competitive tensions and facilitating smoother shared system development may require innovative approaches, such as establishing robust, neutral arbitration or mediation mechanisms, to bridge this trust deficit.

Concurrently, the increasing sophistication and adoption of competitive intelligence tools, exemplified by platforms like DrugPatentWatch, highlight a market-driven adaptation to these barriers.⁶⁹ These tools empower generic companies to actively overcome the information asymmetry created by brand companies’ control over samples and REMS data. By providing granular data on litigation, patent expiry, regulatory status, and market dynamics, competitive intelligence enables generic companies to better predict market entry opportunities, identify potential obstacles, and strategically plan their challenges. This demonstrates that while legislative and regulatory actions are critical, technological solutions for competitive intelligence also play a vital role in making the “fight” for fair competition more informed, efficient, and ultimately, more equitable.

7. Recommendations for Fostering Fair Competition

Breaking the REMS barrier and fostering fair drug competition requires a multi-faceted and sustained approach that addresses legislative, regulatory, and industry-level dynamics. The following recommendations aim to reinforce the balance between patient safety and market accessibility.

Strengthening Enforcement of the CREATES Act

While the CREATES Act has provided a crucial new legal pathway, continuous monitoring of its implementation and outcomes is paramount to ensure its full effectiveness.¹⁵ Further clarity on ambiguities within the Act, such as the precise definition of “sufficient quantities” that brand manufacturers must provide, would enhance its enforceability and potentially reduce future litigation.⁷⁷ This could be achieved through additional judicial precedent or subsequent FDA guidance. Furthermore, it is essential to ensure that the monetary penalties and attorneys’ fees provisions stipulated by the Act are applied consistently and robustly by the courts. Such consistent application would serve as a stronger deterrent against non-compliance, making it economically disadvantageous for brand companies to unlawfully withhold samples.¹⁵

Streamlining FDA Processes for Shared REMS and Waivers

The FDA should continue its efforts to make the shared REMS development process more efficient and transparent. This could involve setting clearer expectations for negotiation timelines between brand and generic manufacturers and offering more active facilitation of these discussions.⁸ Concurrently, the agency should expedite the review and approval of waiver requests for single, shared systems, particularly when brand obstruction is evident or when an aspect of the REMS is protected by a patent or trade secret. Allowing generics to develop separate, comparable systems more readily would significantly reduce the incentive for brand companies to prolong negotiations and thereby delay market entry.⁷

Promoting Greater Transparency in REMS Programs and Sample Access

The FDA’s initiative to publish “name and shame” lists of companies that abuse safety programs has increased transparency and public awareness.¹² Expanding and regularly updating such public disclosures could exert further pressure on brand companies to comply with fair competition principles. Additionally, requiring more detailed public reporting on REMS implementation, including data on sample requests, the reasons for denials, and the progress of shared system negotiations, could shed further light on abusive practices and enable better oversight.

Encouraging Industry Collaboration and Dispute Resolution Mechanisms

While the FDA plays a facilitating role, robust industry working groups and clear, pre-agreed frameworks for cost-sharing and governance are vital for the successful development of shared REMS.¹⁸ Given the inherent competitive tensions, exploring formal mediation or arbitration mechanisms specifically designed for disputes over shared REMS terms could provide a more efficient and less adversarial means of resolving impasses, reducing the need for protracted litigation.

Policy Considerations for Balancing Safety and Competition

A critical ongoing policy consideration involves the regular reassessment of existing REMS programs. This is to determine if their stringent requirements remain necessary given evolving safety data and real-world post-market experience, as demonstrated by the recent removal or streamlining of REMS for drugs like clozapine, Endothelin Receptor Antagonists (ERAs), and certain cell therapies.³⁰ This ensures that REMS do not impose undue burdens or become de facto barriers to competition once their original safety justification diminishes. It is crucial to continue supporting legislative efforts that reinforce the original intent of the Hatch-Waxman Act, ensuring that patient safety programs are not weaponized for anti-competitive purposes. The overarching objective is not to eliminate REMS, but to ensure they are “narrowly tailored” to address specific, serious risks without inadvertently hindering patient access to affordable medicines or distorting market competition.⁷

Deeper Analysis: The Need for Adaptive Regulation and Enforcement and the Interdependence of Policy, Law, and Market Dynamics

The history of REMS abuse and the legislative response, particularly the CREATES Act, clearly demonstrate that static regulatory frameworks are insufficient to effectively address dynamic market behaviors. The continuous evolution of FDA guidance, coupled with the agency’s willingness to modify or remove unnecessary REMS (as seen with clozapine, ERAs, and cell therapies) ³⁰, further underscores the imperative for regulatory agility. This indicates that effective policy in this domain necessitates a proactive and adaptive approach, moving beyond merely reactive measures. It requires continuous assessment of REMS effectiveness, a readiness to modify or remove them when justified by real-world data, and the implementation of robust enforcement mechanisms that can evolve in response to new industry tactics.

Ultimately, the “fight” for fair drug competition is not a singular legal battle or a isolated regulatory challenge. It is an intricate interplay where legislative action, such as the CREATES Act, creates new legal avenues; regulatory bodies like the FDA and FTC issue guidance and enforcement actions; and market participants, including brand and generic companies, continuously adapt their strategies, often leveraging competitive intelligence tools. This complex interdependence highlights that no single solution will fully “break the barrier.” Instead, a sustained and coordinated effort across legislative, regulatory, and legal fronts, complemented by industry’s strategic adaptation, is necessary to continuously re-balance the scales between pharmaceutical innovation, patient safety, and the critical goal of ensuring affordable and accessible medications for all.

Conclusion

Risk Evaluation and Mitigation Strategies (REMS), while foundational to ensuring the safe use of high-risk medications, have been demonstrably co-opted by some brand-name pharmaceutical manufacturers to impede fair competition. The deliberate tactics of withholding drug samples essential for generic bioequivalence testing and prolonging shared REMS negotiations have created significant economic burdens, costing the U.S. healthcare system billions of dollars annually and directly limiting patient access to more affordable medicines. This subversion of REMS’ public health purpose has undermined the pro-competitive intent of the Hatch-Waxman Act, extending monopolies beyond their lawful intellectual property duration.

The enactment of the CREATES Act in 2019 represents a pivotal legislative response, providing generic and biosimilar manufacturers with a crucial private right of action to challenge these anti-competitive practices. This has introduced a more direct and potentially swifter legal remedy compared to the previous reliance on complex antitrust litigation. Early indications from post-CREATES Act cases suggest its potential to deter abusive behaviors. Concurrently, the FDA’s evolving guidance and willingness to reassess and, where appropriate, streamline or remove burdensome REMS, signal a recognition of the need to balance safety with accessibility.

Moving forward, a comprehensive and adaptive strategy is essential to solidify fair competition. This includes rigorous enforcement of the CREATES Act, clarifying any remaining legal ambiguities, and continuing to streamline FDA processes for shared REMS and waivers. Promoting greater transparency in REMS implementation and fostering industry collaboration through effective dispute resolution mechanisms are also critical. Fundamentally, there must be an ongoing commitment to re-evaluate existing REMS programs to ensure their requirements remain proportionate to the risks and do not inadvertently hinder patient access or serve as instruments of anti-competitive behavior. Only through a concerted effort across legislative, regulatory, and industry fronts can the REMS barrier be truly broken, fostering a pharmaceutical market that serves both patient safety and the imperative of affordable access to life-saving medications.